• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    5/30/25 4:15:35 PM ET
    $HUM
    Medical Specialities
    Health Care
    Get the next $HUM alert in real time by email
    false000004907100000490712025-05-302025-05-30

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
     

    FORM 8-K
     
     

    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 30, 2025 (May 30, 2025)
     
     

    Humana Inc.
    (Exact name of registrant as specified in its charter)
     


     
             
    DE
     
    1-5975
     
    61-0647538
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)

    500 W. Main Street, Louisville, KY 40202
    (Address of principal executive offices, and zip code)
    (502) 580-1000
    Registrant’s telephone number, including area code
     
    (Former name or former address, if changed since last report)
     
     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
     
             
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock
     
    HUM
     
    New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     
     


     
    Item 1.01
    Entry into a Material Definitive Agreement.

    On May 30, 2025, Humana Inc. (the “Company”) entered into a $5.0 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Bank National Association, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners (the “Revolving Credit Agreement”), which amends and restates that certain existing unsecured revolving credit agreement, dated as of June 2, 2023, with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners (the “Existing 5-Year Credit Agreement”). The Revolving Credit Agreement (i) increases the amount of the commitments under the Existing 5-Year Credit Agreement from $2.642 billion to $5.0 billion and (ii) replaces the Company’s existing 364-day $2.1 billion unsecured revolving credit agreement, dated as of May 31, 2024, with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners, which has expired in accordance with its terms.
    Loans under the Revolving Credit Agreement bear interest at Term SOFR, Daily Simple SOFR or the base rate plus a spread. The Company will pay an annual facility fee under the Revolving Credit Agreement regardless of utilization.
    The Revolving Credit Agreement contains customary covenants, including a maximum debt to capitalization covenant, as well as customary events of default. The terms of the Revolving Credit Agreement also include standard provisions related to conditions of borrowing, including customary representations and warranties. In addition, the Revolving Credit Agreement permits the incurrence up to $1.0 billion of incremental commitments.
    We have other relationships, including financial advisory and banking, with some parties to the Revolving Credit Agreement.
    As of May 30, 2025, we have no borrowings outstanding under the Revolving Credit Agreement and approximately $14.7 million of issued and undrawn letters of credit under the Revolving Credit Agreement. Accordingly, as of May 30, 2025, we have approximately $4.98 billion of remaining borrowing capacity under the Revolving Credit Agreement.
    The foregoing description of the Revolving Credit Agreement does not purport to be complete. For an understanding of the terms and provisions of the Revolving Credit Agreement, reference should be made to the copy of the Revolving Credit Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the six months ending June 30, 2025.
     
    Item 2.03
    Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

    The information described above under Item 1.01 of this Current Report on Form 8-K is also responsive to Item 2.03 of this Current Report on Form 8-K and is incorporated by reference into this Item 2.03.
     
    Item 9.01
    Financial Statements and Exhibits.

    (d) Exhibits:
     
         
    Exhibit
    No.
     
    Description
       
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     
    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
     
         
    HUMANA INC.
       
    BY:
     
    /s/ John-Paul Felter
     
     
    John-Paul Felter
     
     
    Senior Vice President, Chief Accounting Officer and Controller
    (Principal Accounting Officer)

    Dated: May 30, 2025
    Get the next $HUM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HUM

    DatePrice TargetRatingAnalyst
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    11/6/2024$247.00 → $308.00Underperform → Neutral
    BofA Securities
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    10/8/2024$308.00Mkt Perform → Outperform
    Bernstein
    10/7/2024$402.00 → $261.00Buy → Hold
    TD Cowen
    10/7/2024$519.00 → $253.00Buy → Hold
    Jefferies
    10/3/2024$392.00 → $274.00Overweight → Neutral
    Piper Sandler
    10/2/2024$376.00 → $247.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/16/24 4:29:43 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/14/24 10:02:59 AM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/13/24 5:06:27 PM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Financials

    Live finance-specific insights

    See more
    • Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

      Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

      4/30/25 6:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Board Declares Payment of Quarterly Dividend to Stockholders

      Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on July 25, 2025 to stockholders of record as of the close of business on June 27, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military serv

      4/17/25 6:30:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. Announces Dates for First Quarter 2025 Earnings and June Investor Conference

      Humana Inc. (NYSE:HUM) will release financial results for the first quarter 2025 (1Q25) and host a live question-and-answer session on Wednesday, April 30, 2025. Additionally, the company will host an Investor Conference on Monday, June 16, 2025. 1Q25 Earnings Humana will release its 1Q25 financial results, as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on April 30, 2025. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. A webcast of the 1Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gc

      4/3/25 4:15:00 PM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

      4 - HUMANA INC (0000049071) (Issuer)

      5/16/25 4:48:13 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Smith Gordon

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:46:09 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Hilzinger Kurt J

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:45:12 PM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Foundation Donates $50,000 to Support Long-Term Recovery in Tornado-Impacted Kentucky Communities

      The Humana Foundation, philanthropic arm of Humana Inc. (NYSE:HUM), announced today a $50,000 contribution to advance sustained recovery efforts in Kentucky communities devastated by the most recent wave of severe storms and tornadoes. On Friday, May 16, powerful storms swept across the state, causing widespread destruction—particularly in Laurel and Pulaski Counties. The city of London experienced considerable damage, and residents across the region continue to grapple with the aftermath of a relentless spring tornado season. At least 19 lives have been lost in what has become yet another tragic weather disaster. In response to the recent tornadoes, the Humana Foundation is directing $50

      5/22/25 2:46:00 PM ET
      $HUM
      Medical Specialities
      Health Care
    • CenterWell Specialty Pharmacy Takes National Patient Choice Award

      Organization Recognized for Seventh Time in Eight Years CenterWell Specialty Pharmacy has once again received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category, its seventh such win in the past eight years. The award recognizes best-in-class customer satisfaction and commitment to patient care by a specialty pharmacy. "There's something so rewarding about seeing our team's dedication to excellent care and support being recognized year after year by the people we serve," said Guillermo Sollberger, senior vice president of CenterWell Specialty Pharmacy and CenterWell Pharmacy. "We know that many of the patients who require specialty drugs are feeling overwhelmed, so

      5/13/25 9:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

      Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

      4/30/25 6:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Leadership Updates

    Live Leadership Updates

    See more
    • Humana Announces CFO Transition

      Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So

      12/3/24 8:05:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Appoints Michelle O'Hara as Chief Human Resources Officer

      Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier

      11/12/24 12:30:00 PM ET
      $HUM
      Medical Specialities
      Health Care
    • Define Ventures Appoints Bruce Broussard as Venture Partner

      The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie

      10/22/24 9:00:00 AM ET
      $EVH
      $HIMS
      $HUM
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Humana upgraded by Raymond James with a new price target

      Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00

      5/1/25 7:42:13 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana upgraded by BofA Securities with a new price target

      BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously

      11/6/24 8:21:46 AM ET
      $HUM
      Medical Specialities
      Health Care
    • KeyBanc Capital Markets initiated coverage on Humana

      KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight

      10/11/24 7:47:34 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    SEC Filings

    See more
    • Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - HUMANA INC (0000049071) (Filer)

      6/2/25 7:30:12 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - HUMANA INC (0000049071) (Filer)

      5/30/25 4:15:35 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Humana Inc.

      10-Q - HUMANA INC (0000049071) (Filer)

      4/30/25 9:29:51 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

      4 - HUMANA INC (0000049071) (Issuer)

      5/16/25 4:48:13 PM ET
      $HUM
      Medical Specialities
      Health Care
    • Mesquita Jorge S. bought $200,066 worth of Humana Common (545 units at $367.09) (SEC Form 4)

      4 - HUMANA INC (0000049071) (Issuer)

      2/21/24 10:37:23 AM ET
      $HUM
      Medical Specialities
      Health Care